Based on the findings derived from experimental ARDS models in mice, rats, and porcine, blockage of visfatin activity via injection of inhibitory antibodies may have potential to treat severely ill COVID-19 patients. This evidence concerns the gene NAMPT and acute respiratory distress syndrome.